YOLFTbeta
Pharmosa Biopharm Inc.

Pharmosa Biopharm Inc.

6875 · TWO · Healthcare / Biotechnology

25.40TWD+0.70 (+2.83%)

Price History

Full chart

Market Stats

Previous Close24.70
Open25.80
Day Range24.95 – 25.80
52-Week Range29.85 – 65.00
Volume34.37K
Market Cap3.86B
P/E (TTM)0.00
Forward P/E0.00
EPS-2.71
Dividend Yield0.00%
Beta0.19
50-Day Avg32.66
200-Day Avg38.48

About

Pharmosa Biopharm Inc., a biotechnology company, focuses on research and development of new drugs in Taiwan. The company develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease, which has completed a Phase I clinical trial. The company was formerly known as Pharmosa Limited and changed its name to Pharmosa Biopharm Inc. in October 2016. Pharmosa Biopharm Inc. was incorporated in 2000 and is headquartered in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Pei Kan Ph.D.
  • Employees0
  • HeadquartersNo. 508, Section 7, Zhongxiao E. Rd., Taipei, Taiwan, Taiwan
  • Websitehttps://www.pharmosa.com.tw

Leadership

  • Dr. Pei Kan Ph.D.President, GM & Director
  • Mr. Hui-An PaoVice President of Operations
  • Ms. Ru-Yun Lin M.B.A.Vice President of Administration · b. 1966
  • Mr. Wei Shu LuSenior Director of Strategic & Project Development Division
  • Mr. Frank LiangSenior Director of Process Development Division
  • Ms. Shu-Ping YangVice President of Finance & Accounting

Financials

Income Statement

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--0314.50M167.57M67.27M
Growth (%)-----46.72%-59.86%
Cost of Revenue---040.66M54.23M
Gross Profit---314.50M126.90M13.03M
Gross Margin---100.00%75.73%19.37%
Operating Expense---303.19M345.47M415.89M
Operating Income-177.84M-255.26M-265.86M11.31M-218.57M-402.86M
Operating Margin---3.60%-130.43%-598.88%
EBITDA-167.22M-243.47M-253.16M34.63M-138.43M-350.27M
EBITDA Margin---11.01%-82.61%-520.70%
Net Income-181.70M-256.48M-266.51M8.46M-166.65M-383.85M
Net Income Margin---2.69%-99.45%-570.63%
R&D175.31M240.81M242.31M276.97M294.79M366.65M
R&D as % of Total Revenue---88.07%175.92%545.06%
Interest Expense3.86M1.21M649.00K2.86M2.42M2.10M
Interest Expense % of Total Revenue---0.91%1.44%3.12%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-543.27M586.37M799.37M1.33B2.16B1.75B
Total Liabilities-137.44M54.93M38.25M195.99M225.66M190.57M
Total Equity-405.83M531.43M761.12M1.14B1.94B1.56B
Cash84.89M414.54M461.46M672.51M974.06M749.44M631.23M
Total Debt-124.43M37.09M21.19M144.37M--
Net Debt-84.89M-290.10M-424.37M-651.32M-829.69M--

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--181.45M-237.51M-258.31M42.42M-127.16M-357.48M
Financing Cash Flow-596.81M279.68M479.52M352.97M--
Capital Expenditure07.05M3.25M10.19M81.47M165.97M119.35M
Free Cash Flow--188.50M-240.75M-268.50M-39.05M-293.13M-476.83M
FCF to OCF-103.89%101.37%103.94%-92.04%230.51%133.39%

Key Statistics & Ratios

Market Cap3.86B
Enterprise Value3.52B
Trailing P/E0.00
Forward P/E0.00
Price / Sales72.36
Price / Book3.01
EPS-2.71
Book Value10.58
Revenue (TTM)53.38M
Gross Profit (TTM)10.59M
EBITDA-380.64M
Profit Margin0.00%
Operating Margin-762.03%
Return on Equity-22.83%
Return on Assets-13.77%
Shares Outstanding129.18M
Shares Float76.27M
Beta0.19
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%